adapted Chicago Run running program for Arthrogryposis

Phase-Based Progress Estimates
Arthrogryposis+6 More
adapted Chicago Run running program - Behavioral
< 65
All Sexes
What conditions do you have?

Study Summary

This trial is testing a new program to help young people with disabilities stay fit, by providing accessible running programs at community locations.

Eligible Conditions
  • Arthrogryposis
  • Myelomeningocele
  • Gross Motor Development Delay
  • Cerebral Palsy
  • Motor Skills Disorders

Treatment Effectiveness

Study Objectives

4 Primary · 2 Secondary · Reporting Duration: at 8 weeks

at 8 weeks
30 second walk test
6 min walk test
Resting heart rate
Selective Control Assessment of the Lower Extremity (SCALE)
at 8 weeks.
Goal attainment scale

Trial Safety

Trial Design

1 Treatment Group

Running group
1 of 1

Experimental Treatment

25 Total Participants · 1 Treatment Group

Primary Treatment: adapted Chicago Run running program · No Placebo Group · N/A

Running group
Experimental Group · 1 Intervention: adapted Chicago Run running program · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: at 8 weeks

Who is running the clinical trial?

Northwestern UniversityLead Sponsor
1,432 Previous Clinical Trials
769,512 Total Patients Enrolled
Spencer FoundationUNKNOWN
American Academy of Cerebral Palsy and Developmental MedicineUNKNOWN
1 Previous Clinical Trials
20 Total Patients Enrolled
Chicago RunUNKNOWN

Eligibility Criteria

Age < 65 · All Participants · 1 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 30th, 2021

Last Reviewed: November 17th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.